DEPARTMENT OF HEALTH SERVICES

Division Medicaid Services F-00163 (04/2023)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH PRIOR AUTHORIZATION DRUG ATTACHMENT FOR ANTI-OBESITY DRUGS

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Anti-Obesity Drugs Instructions, F-00163A. Prescribers may refer to the Forms page of the ForwardHealth Portal at https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Prescribers and pharmacy providers may call the Drug Authorization and Policy Override Center at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION					
1. Name – Member (Last, First, Middle Initial)					
2. Member ID Number	3. Date of Birth – Member				
SECTION II – PROVIDER INFORMATION					
4. Name – Prescriber					
5. Address – Prescriber (Street, City, State, Zip+4 Code)					
6. Phone Number – Prescriber	7. National Provider Identifier (NPI) – Prescriber				
8. Name – Billing Provider					
9. NPI – Billing Provider					
SECTION III – PRESCRIPTION INFORMATION					
10. Drug Name	11. Drug Strength				
12. Date Prescription Written	13. Refills				
14. Directions for Use					
SECTION IV – CLINICAL INFORMATION					
15. Diagnosis Code and Description					
16. Height – Member (Inches)	17. Weight – Member (Pounds)				



18. Date N	18. Date Member's Weight Was Measured		19. Body Mass Index (BMI) – Member (lb / in²)				
20. Goal Weight – Member (Pounds)			BMI = <u>703 X (weight in pounds)</u> (height in inches) ²				
For an initial prior authorization (PA) request, the prescriber must complete Sections IV A and IV B. For a renewal PA request, the prescriber must complete Section IV A.							
SECTION IV A – INITIAL AND RENEWAL COVERAGE REQUIREMENTS							
21. Enter the member's age.							
Note: Members must be 18 years of age or older for approval of PA requests for anti-obesity drugs, except for Evekeo, Saxenda, Wegovy, and Xenical. Members must be 12 years of age or older to take Evekeo, Saxenda, Wegovy, and Xenical.							
22. Is the	mem	ber pregnant or nursing?		☐ Yes		No	
23. Does the member have a history of an eating disorder (for example, anorexia, bulimia, or binge eating disorder)?			☐ Yes		No		
24. Has the prescriber evaluated the member and determined that they do not have any medical or medication contraindications to treatment with the anti-obesity drug being requested? Yes No					No		
25. Does the member have a medical history of substance abuse or misuse?				No			
SECTION IV B – INITIAL COVERAGE REQUIREMENTS							
26. BMI R	equir	rements (Check A, B, C, or D.)					
A. The member is 18 years of age or older (or 12 years of age or older for Evekeo requests only) and has a BMI greater than or equal to 30.							
B. The member is 18 years of age or older (or 12 years of age or older for Evekeo requests only) and has a BMI greater than or equal to 27 but less than 30 and has two or more of the following risk factors. Check the member's current risk factors:							
		Coronary Heart Disease					
		Dyslipidemia					
		Hypertension					
		Sleep Apnea					
		Type 2 Diabetes Mellitus					
C. 🗖	C. ☐ Saxenda PA requests for members 12–17 years of age: The member has a body weight above 132 pounds and a BMI corresponding to 30 or greater for adults by international cut-offs.						
D. 🗖	D. Wegovy and Xenical PA requests for members 12–17 years of age: The member has a BMI greater than or equal to the 95th percentile standardized by age and sex.						
27. Has the member participated in a weight loss treatment plan (for example, nutritional counseling, an exercise regimen, or a calorie-restricted diet) in the past six months, and will the member continue to follow this treatment plan while taking an anti-obesity drug? □ Yes □ No							
If yes, describe the treatment plan in the space provided.							

SECTION V – AUTHORIZED SIGNATURE	
28. SIGNATURE – Prescriber	29. Date Signed – Prescriber
SECTION VI – ADDITIONAL INFORMATION	

30. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may also be included here.